1. Consolidated guidelines on the use of antiretroviral drugs for treating and
preventing HIV infection Recommendations for a public health approach - Second edition. WHO. http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed Jan 9, 2017.
2. 愛滋病統計資料 105 年統計月報. 衛生福利部疾病管制署.
http://www.cdc.gov.tw/professional/info.aspx?treeid=7B56E6F932B49B90&nowt reeid=2F13020F8A921CCB&tid=97D39D2BB81D32E9. Accessed Jan 9, 2017.
3. 愛滋病檢驗及治療指引(第四版). 衛生福利部疾病管制署.
http://www.cdc.gov.tw/professional/infectionreportinfo.aspx?treeid=7B56E6F932 B49B90&nowtreeid=2560135C8787ACC9&tid=834BBE0B04ACD373.
Accessed Jan 9, 2017.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
Department of Health and Human Services.
http://www.aidsinfo.nih.gov/ContentFiles/Adul-tandAdolescentGL.pdf. Accessed Jan 9, 2017.
5. 新聞稿：愛滋用藥大利多，六月起與先進國家齊步.
http://www.cdc.gov.tw/professional/info.aspx?treeid=cf7f90dcbcd5718d&nowtree id=f94e6af8daa9fc01&tid=A5A80A4E91A853EC. Accessed Jan 10, 2017.
6. 抗人類免疫缺乏病毒藥品處方使用規範. 衛生福利部 疾病管制署.
https://www.syndriver.com/portal/sharing/1397c70f215e4ac4a0e3ef094227ea6c.
Accessed Jan 9, 2017.
7. ATC/DDD Index 2017. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/. Accessed Jan 11, 2017.
8. 西藥、醫療器材、含藥化粧品許可證查詢. 衛生福利部食品藥物管理署.
http://www.fda.gov.tw/MLMS/H0001.aspx. Accessed Jan 11, 2017.
9. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Canadian Agency for Drugs and Technologies in Health.
https://www.cadth.ca/elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide.
Accessed Jan 12, 2017.
10. Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide, fixed-dose combination tablet, 150 mg/ 150 mg/200 mg/10 mg, Genvoya® . Pharmaceutical Benefits Advisory Committee (PBAC). Australian Government Department of Health.
http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2015-11/files/
elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-psd-november-2015.p
df. Accessed Jan 12, 2017.
11. National Institute for Health and Care Excellence. http://www.nice.org.uk/.
Accessed Jan 17, 2017.
12. elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (Genvoya).
Scottish Medicines Consortium (SMC).
https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1142_16_elvitegravir _cobicistat_emtricitabine_tenofovir_alafenamide_fumarate_Genvoya/elvitegravir _cobicistat_emtricitabine_tenofovir_alafenamide_fumarate_Genvoya. Accessed Jan 12, 2017.
13. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. Journal of acquired immune deficiency syndromes (1999) 2014; 67(1):
52-58.
14. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3,
non-inferiority trials. Lancet (London, England) 2015; 385(9987): 2606-2615.
15. Wohl D, Oka S, Clumeck N, et al. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. Journal of acquired immune deficiency syndromes (1999) 2016; 72(1): 58-64.
16. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised,
active-controlled, multicentre, open-label, phase 3, non-inferiority study. The Lancet Infectious diseases 2016; 16(1): 43-52.
17. 衛生福利部. 104 年我國愛滋病疫情現況概述.
http://www.mohw.gov.tw/cht/DOS/DisplayStatisticFile.aspx?d=55681&f=21853.
Accessed Jan 23, 2017.
18. 衛生福利部疾病管制署. 愛滋感染者醫療需求及服務利用分析; 2014.
19. WHO ATC/DDD Index 2017. https://www.whocc.no/atc_ddd_index/. Accessed Jan 19, 2017.
20. 抗人類免疫缺乏病毒藥品處方使用規範.衛生福利部疾病管制署, 2016.
21. 衛生福利部. 愛滋防治第六期五年計畫: 衛生福利部; 2015.
附錄
附錄一 療效評估文獻搜尋記錄
資料庫 查詢日期 關鍵字 篇數
PubMed 2017/01/24 1 "HIV-1/drug effects"[Mesh] OR "HIV
Infections/drug therapy"[Mesh] OR "Anti-HIV Agents"[Mesh] OR "HIV"[tiab]
285,100
2 "elvitegravir"[tiab] AND ("Cobicistat"[Mesh]
OR "cobicistat"[tiab]) AND ("Emtricitabine"[Mesh] OR
"emtricitabine"[tiab]) AND "tenofovir alafenamide"[tiab]
25
3 #1 AND #2 23
4 #3 Filters: Systematic Reviews; Meta-Analysis 1 5 #3 Filters: Randomized Controlled Trial 6 6 #3 Filters: Comparative Study 2 Cochrane
Library
2017/01/24 "elvitegravir":ti,ab,kw and
"cobicistat":ti,ab,kw and
"emtricitabine":ti,ab,kw and "Tenofovir alafenamide":ti,ab,kw and HIV:ti,ab,kw
23
附錄二 經濟評估文獻搜尋記錄
資料庫 查詢日期 # 關鍵字 篇數
PubMed 2017/01/18 1 "hiv"[MeSH Terms] OR "hiv"[All Fields] 312,089
2 (elvitegravir/cobicistat/emtricitabine/tenofovir[All Fields] AND alafenamide[All Fields]) OR
genvoya[All Fields]
11
3 "economics"[Subheading] OR "economics"[All Fields] OR "cost"[All Fields] OR "costs and cost analysis"[MeSH Terms] OR ("costs"[All Fields]
AND "cost"[All Fields] AND "analysis"[All Fields]) OR "costs and cost analysis"[All Fields]
696,653
4 #1 AND #2 AND #3 0
Cochrane Library
2017/01/18 1
'HIV and genvoya and cost
0
CRD 2017/01/18 1 (HIV) AND (genvoya) AND (cost) IN HTA 0
Embase 2017/01/18 1 hiv 337,359
2 genvoya 15
3 cost 679,561
4 #1 AND #2 AND #3 2